{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:04:25Z","timestamp":1793397865304,"version":"4.5.0"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011094","name":"public health agency of canada","doi-asserted-by":"publisher","award":["contract no. C45237"],"award-info":[{"award-number":["contract no. C45237"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02866-4","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:16:37Z","timestamp":1761650197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-7229","authenticated-orcid":false,"given":"Jennifer","family":"Pillay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Guitard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Zakher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2866_CR1","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian cancer statistics 2023. Candian Cancer Society. 2023. Available from: https:\/\/cdn.cancer.ca\/-\/media\/files\/research\/cancer-statistics\/2023-statistics\/2023_pdf_en.pdf. Accessed 7 July 2024."},{"key":"2866_CR2","unstructured":"Navaneelan T. Trends in the incidence and mortality of female reproductive system cancers. Health at a Glance. Statistics Canada Catologue no 82\u2013624-X. 2015. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-624-x\/2015001\/article\/14095-eng.htm . Accessed 7 July 2024."},{"key":"2866_CR3","unstructured":"Statistics Canada. Cancer incidence by stage in Canada, 2017. Statistics Canada. 2020. Available from: https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/200309\/dq200309b-eng.htm. Accessed 7 July 2024. Accessed 7 July 2024."},{"key":"2866_CR4","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2019. Canadian Cancer Society. 2019. Available from: https:\/\/cdn.cancer.ca\/-\/media\/files\/research\/cancer-statistics\/2019-statistics\/canadian-cancer-statistics-2019-en.pdf. Accessed 7 July 2024."},{"issue":"1","key":"2866_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139.","journal-title":"J Pathol"},{"key":"2866_CR6","unstructured":"Herrero R. Cervical cancer. In: Thun MJ LM, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer epidemiology and prevention, 4th ed. New York, New York: Oxford University Press; 2018. p. 925\u201346."},{"key":"2866_CR7","unstructured":"Candian Cancer Society. HPV and cancer. Available from: https:\/\/www.cancer.ca\/en\/prevention-and-screening\/reduce-cancer-risk\/make-informed-decisions\/get-vaccinated\/hpv-and-cancer\/?region=on . Accessed 7 July 2024."},{"issue":"11","key":"2866_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","volume":"41","author":"HW Chesson","year":"2014","unstructured":"Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660\u20134.","journal-title":"Sex Transm Dis"},{"key":"2866_CR9","unstructured":"World Health Organization. Human papillomavirus and cancer. 2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papilloma-virus-and-cancer. Accessed 7 July 2024."},{"key":"2866_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1750-9378-4-8","volume":"4","author":"M Schiffman","year":"2009","unstructured":"Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8.","journal-title":"Infect Agent Cancer"},{"key":"2866_CR11","unstructured":"Bruni L, Alberto G, Serrano B, Mena M, Collado JJ, G\u00f3mez D, et al. Fact sheet: Canada: Human papillomavirus and related cancers. In: Human papillomavirus and related diseases in Canada. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary report 10 March 2023. Barcelona, Spain: ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2023. Available from: https:\/\/hpvcentre.net\/statistics\/reports\/CAN_FS.pdf. Accessed 7 July 2024."},{"key":"2866_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-235","volume":"11","author":"AC Tricco","year":"2011","unstructured":"Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S. Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis. BMC Infect Dis. 2011;11:235.","journal-title":"BMC Infect Dis"},{"key":"2866_CR13","unstructured":"Ramirez PT, Salvo G. Cervical cancer: Merck manual. 2019. Available from: https:\/\/www.merckmanuals.com\/en-ca\/home\/women-s-health-issues\/cancers-of-the-female-reproductive-system\/cervical-cancer. Accessed 7 July 2024."},{"key":"2866_CR14","doi-asserted-by":"crossref","unstructured":"Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003(31):14\u20139.","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476"},{"key":"2866_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k499","volume":"360","author":"K Tainio","year":"2018","unstructured":"Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, C\u00e1rdenas J, Glazer-Livson S, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.","journal-title":"BMJ"},{"issue":"5","key":"2866_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","volume":"9","author":"MR McCredie","year":"2008","unstructured":"McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425\u201334.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2866_CR17","first-page":"451","volume":"64","author":"WA McIndoe","year":"1984","unstructured":"McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol. 1984;64(4):451\u20138.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2866_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01538-9","volume":"10","author":"A Gates","year":"2021","unstructured":"Gates A, Pillay J, Reynolds D, Stirling R, Traversy G, Korownyk C, et al. Screening for the prevention and early detection of cervical cancer: protocol for systematic reviews to inform Canadian recommendations. Syst Rev. 2021;10(1):2.","journal-title":"Syst Rev"},{"key":"2866_CR19","unstructured":"Public Health Agency of Canada. Human papillomavirus (HPV) vaccines. 2023. In: Canadian Immunization Guide. Government of Canada. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/canadian-immunization-guide.html. Accessed 7 July 2024."},{"key":"2866_CR20","unstructured":"Public Health Agency of Canada. Immunizing agents quthorized for use in Canada. In: Canadian Immunization Guide. Government of Canada. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/canadian-immunization-guide.html. Accessed 7 July 2024."},{"key":"2866_CR21","unstructured":"Canadian Partnership Against Cancer. HPV immunization for the prevention of cervical cancer. 2021. Available from: https:\/\/www.partnershipagainstcancer.ca\/topics\/hpv-immunization-policies\/ . Accessed 7 July 2024."},{"issue":"1","key":"2866_CR22","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","volume":"1","author":"M Brisson","year":"2016","unstructured":"Brisson M, B\u00e9nard \u00c9, Drolet M, Bogaards JA, Baussano I, V\u00e4nsk\u00e4 S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8\u201317.","journal-title":"Lancet Public Health"},{"key":"2866_CR23","unstructured":"Chao Y-S, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. HPV testing for primary cervical cancer screening: a health technology assessment. Canadian Agency for Drugs and Technologies in Health (CADTH). 2019. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543088\/. Accessed 7 July 2024."},{"issue":"7","key":"2866_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2018.10400","volume":"320","author":"J Melnikow","year":"2018","unstructured":"Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyric MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(7):687\u2013705.","journal-title":"JAMA"},{"key":"2866_CR25","unstructured":"Canadian Partnership Against Cancer. HPV screening and follow-up pathway. 2025. Available from: https:\/\/www.partnershipagainstcancer.ca\/topics\/hpv-screening-pathway\/summary\/. Accessed 7 July 2024."},{"key":"2866_CR26","unstructured":"Cancer Care Ontario. Follow-up of self-collected human papillomavirus (HPV) testing. Available from: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/cancer-continuum\/screening\/resources-healthcare-providers\/self-collected-HPV#:~:text=People%20with%20self%2Dcollected%20HPV%2Dpositive%2C%20HPV%2Dinvalid,earliest%20convenience%2C%20within%203%20months. Accessed 7 April 2025."},{"key":"2866_CR27","unstructured":"Canadian Partnership Against Cancer. Cervical cancer screening in Canada: 2019\u20132020 environmental scan. 2021. Available from: https:\/\/s22457.pcdn.co\/wp-content\/uploads\/2021\/01\/cervical-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf. Accessed 7 July 2024."},{"key":"2866_CR28","unstructured":"Canadian Partnership Against Cancer. Cervical screening in Canada: 2021\/2022 environmental scan. 2022. Available from: https:\/\/www.partnershipagainstcancer.ca\/topics\/cervical-cancer-screening-in-canada-2021-2022\/summary\/. Accessed 7 July 2024."},{"key":"2866_CR29","unstructured":"Statistics Canada. Health fact sheets. Cancer screening, 2017. Government of Canada. 2018. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-625-x\/2018001\/article\/54977-eng.htm. Accessed 7 July 2024."},{"issue":"6","key":"2866_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3747\/co.22.2599","volume":"22","author":"S Ahmed","year":"2015","unstructured":"Ahmed S, Shahid RK, Episkenew JA. Disparity in cancer prevention and screening in aboriginal populations: recommendations for action. Curr Oncol. 2015;22(6):417\u201326.","journal-title":"Curr Oncol"},{"issue":"6","key":"2866_CR31","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1097\/AOG.0b013e31823ed1c1","volume":"118","author":"Committee on Health Care for Underserved Women","year":"2011","unstructured":"Committee on Health Care for Underserved Women. Committee opinion no. 512: health care for 943 transgender individuals. Obstet Gynecol. 2011;118(6):1454\u20138.","journal-title":"Obstet Gynecol"},{"key":"2866_CR32","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107 . Accessed 7 July 2024."},{"key":"2866_CR33","unstructured":"Canadian Partnership Agaisnt Cancer. Action plan for the elimination of cervical cancer in Canada 2020\u20132030. 2020. Available from: https:\/\/s22438.pcdn.co\/wp-content\/uploads\/2020\/11\/Elimination-cervical-cancer-action-plan-EN.pdf . Accessed 7 July 2024."},{"key":"2866_CR34","doi-asserted-by":"crossref","unstructured":"Schunemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2014;186(3):E123\u201342.","DOI":"10.1503\/cmaj.131237"},{"issue":"1","key":"2866_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12955-017-0621-0","volume":"15","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2866_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20(4):644\u201350.","journal-title":"Value Health"},{"issue":"7","key":"2866_CR37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"SJ Curry","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674\u201386.","journal-title":"JAMA"},{"issue":"1","key":"2866_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1503\/cmaj.121505","volume":"185","author":"Canadian Task Force on Preventive Health Care","year":"2013","unstructured":"Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013;185(1):35\u201345.","journal-title":"CMAJ"},{"key":"2866_CR39","unstructured":"Cancer Council Australia Cervical Cancer Screening Guidelines Working. National Cervical Screening Program: guidelines for the management of screen\u2010detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Cancer Council Australia. 2022. Available from: https:\/\/www.cancer.org.au\/clinical-guidelines\/cervical-cancer\/cervical-cancer-screening. Accessed 7 July 2024."},{"key":"2866_CR40","unstructured":"UK National Screening Committee. The UK NSC recommendation on cervical cancer screening in women. 2019. Available from: https:\/\/view-health-screening-recommendations.service.gov.uk\/cervical-cancer\/. Accessed 7 July 2024."},{"issue":"17","key":"2866_CR41","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/S0959-8049(00)00317-8","volume":"36","author":"M van Ballegooijen","year":"2000","unstructured":"van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer. 2000;36(17):2244\u20136.","journal-title":"Eur J Cancer"},{"key":"2866_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2866_CR43","unstructured":"Chao Y-S, Clark M, Carson E, Weeks L, Moulton K, McFaul S, et al. CADTH Optimal Use Report. HPV testing for primary cervical cancer screening: a health technology assessment. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543088\/. Accessed 7 July 2024."},{"issue":"4","key":"2866_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. Grade guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395\u2013400.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR45","unstructured":"United Nations Development Programme. Human development report. 2021\u201322. Available from: https:\/\/hdr.undp.org\/content\/human-development-report-2021-22 . Accessed 7 July 2024."},{"key":"2866_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jclinepi.2018.01.013","volume":"111","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nunez JJ, Akl EA, Hazlewood G, et al. Grade guidelines: 19. assessing the certainty of evidence in the importance of outcomes or values and preferences-risk of bias and indirectness. J Clin Epidemiol. 2019;111:94\u2013104.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2018.05.011","volume":"111","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Coello PA, Guyatt GH, Yepes-Nunez JJ, Akl EA, Hazlewood G, et al. Grade guidelines: 20. assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83\u201393.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR48","doi-asserted-by":"crossref","unstructured":"Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin\u2010Hirsch PPL, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017; 11(11):CD012847.","DOI":"10.1002\/14651858.CD012847"},{"key":"2866_CR49","doi-asserted-by":"crossref","unstructured":"Kyrgiou M, Mitra A, Arbyn M, Paraskevaidi M, Athanasiou A, Martin\u2010Hirsch PPL, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2015(9)LCD008478.","DOI":"10.1002\/14651858.CD008478.pub2"},{"key":"2866_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.","journal-title":"BMJ"},{"key":"2866_CR51","doi-asserted-by":"crossref","unstructured":"Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev. 2011(5):CD002834","DOI":"10.1002\/14651858.CD002834.pub2"},{"issue":"3","key":"2866_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Mustafa RA, Sch\u00fcnemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85\u20137.","journal-title":"Evid Based Med"},{"key":"2866_CR53","unstructured":"Alberta PROMs & EQ-5D Research & Support Unit. Alberta Population Norms for EQ-5D-5L, 2018. Available from: https:\/\/sites.google.com\/ualberta.ca\/apersu\/about-eq-5d\/eq-5d-population-norms. Accessed 7 July 2024."},{"key":"2866_CR54","unstructured":"Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. 2006. Available from: https:\/\/www.lancaster.ac.uk\/media\/lancaster-university\/content-assets\/documents\/fhm\/dhr\/chir\/NSsynthesisguidanceVersion1-April2006.pdf. Accessed 7 July 2024."},{"key":"2866_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"2866_CR56","unstructured":"Higgins JPT, Li T, Deeks JJ (editors). Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook. Accessed 7 July 2024."},{"issue":"68","key":"2866_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20680","volume":"20","author":"HC Kitchener","year":"2016","unstructured":"Kitchener HC, Gittins M, Rivero-Arias O, Tsiachristas A, Cruickshank M, Gray A, et al. A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC). Health Technol Assess. 2016;20(68):1\u2013138.","journal-title":"Health Technol Assess"},{"issue":"2","key":"2866_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2307\/2532311","volume":"48","author":"JN Rao","year":"1992","unstructured":"Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992;48(2):577\u201385.","journal-title":"Biometrics"},{"key":"2866_CR59","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook. Accessed 7 July 2024."},{"issue":"7109","key":"2866_CR60","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629.","journal-title":"BMJ"},{"issue":"11","key":"2866_CR61","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.7326\/M21-2234","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, Mallett S, Takwoingi Y, Davenport CF, Hyde CJ, Whiting PF, et al. QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies. Ann Intern Med. 2021;174(11):1592\u20139.","journal-title":"Ann Intern Med"},{"key":"2866_CR62","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2019 Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 7 July 2024"},{"key":"2866_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2866_CR64","unstructured":"Schunemann H, Brozek J, Guyatt G, Oxman A. GRADE Handbook 2013. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed 7 July 2024."},{"issue":"3","key":"2866_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Mustafa RA, Schunemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85\u20137.","journal-title":"Evid Based Med"},{"issue":"12","key":"2866_CR66","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. Grade guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.12.020","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.020.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142\u201352.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","volume":"137","author":"L Zeng","year":"2021","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G, et al. Grade guidelines 32: grade offers guidance on choosing targets of grade certainty of evidence ratings. J Clin Epidemiol. 2021;137:163\u201375.","journal-title":"J Clin Epidemiol"},{"key":"2866_CR70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. Grade guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126\u201335.","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"2866_CR71","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","volume":"360","author":"R Sankaranarayanan","year":"2009","unstructured":"Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"2866_CR72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2014.02.037","volume":"133","author":"D Vicus","year":"2014","unstructured":"Vicus D, Sutradhar R, Lu Y, Elit L, Kupets R, Paszat L. The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study. Gynecol Oncol. 2014;133(2):167\u201371.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2866_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/IGC.0000000000000305","volume":"25","author":"D Vicus","year":"2015","unstructured":"Vicus D, Sutradhar R, Lu Y, Kupets R, Paszat L. Association between cervical screening and prevention of invasive cervical cancer in Ontario: a population-based case-control study. Int J Gynecol Cancer. 2015;25(1):106\u201311.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"2866_CR74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/sj.bjc.6600974","volume":"89","author":"P Sasieni","year":"2003","unstructured":"Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89(1):88\u201393.","journal-title":"Br J Cancer"},{"issue":"3","key":"2866_CR75","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.24410","volume":"125","author":"P Sasieni","year":"2009","unstructured":"Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer. 2009;125(3):525\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001585","volume":"11","author":"A Castanon","year":"2014","unstructured":"Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50\u201364 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11(1):e1001585.","journal-title":"PLoS Med"},{"key":"2866_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106625","volume":"149","author":"A Castanon","year":"2021","unstructured":"Castanon A, Green LI, Sasieni P. Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: a population-based case-control study. Prev Med. 2021;149:106625.","journal-title":"Prev Med"},{"issue":"3","key":"2866_CR78","first-page":"221","volume":"79","author":"A Andersson-Ellstrom","year":"2000","unstructured":"Andersson-Ellstrom A, Seidal T, Grannas M, Hagmar B. The pap-smear history of women with invasive cervical squamous carcinoma: a case-control study from Sweden. Acta Obstet Gynecol Scand. 2000;79(3):221\u20136.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"2866_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253801","volume":"16","author":"LF Tanaka","year":"2021","unstructured":"Tanaka LF, Schriefer D, Radde K, Schauberger G, Klug SJ. Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: a population-based case-control study. PLoS ONE. 2021;16(7):e0253801.","journal-title":"PLoS ONE"},{"issue":"4","key":"2866_CR80","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ijc.26084","volume":"130","author":"F Azerkan","year":"2012","unstructured":"Azerkan F, Sparen P, Sandin S, Tillgren P, Faxelid E, Zendehdel K. Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer. 2012;130(4):937\u201347.","journal-title":"Int J Cancer"},{"issue":"3","key":"2866_CR81","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ygyno.2017.09.010","volume":"147","author":"P Makkonen","year":"2017","unstructured":"Makkonen P, Heinavaara S, Sarkeala T, Anttila A. Impact of organized and opportunistic Pap testing on the risk of cervical cancer in young women - a case-control study from Finland. Gynecol Oncol. 2017;147(3):601\u20136.","journal-title":"Gynecol Oncol"},{"key":"2866_CR82","doi-asserted-by":"crossref","unstructured":"Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339.","DOI":"10.1136\/bmj.b3115"},{"issue":"11","key":"2866_CR83","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1002\/ijc.28586","volume":"134","author":"PA Dugue","year":"2014","unstructured":"Dugue PA, Lynge E, Rebolj M. Mortality of non-participants in cervical screening: register-based cohort study. Int J Cancer. 2014;134(11):2674\u201382.","journal-title":"Int J Cancer"},{"issue":"8","key":"2866_CR84","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/1055-9965.EPI-12-0162","volume":"21","author":"S Lonnberg","year":"2012","unstructured":"Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1354\u201361.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2866_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002414","volume":"14","author":"J Wang","year":"2017","unstructured":"Wang J, Andrae B, Sundstrom K, Ploner A, Strom P, Elfstrom KM, et al. Effectiveness of cervical screening after age 60 years according to screening history: nationwide cohort study in Sweden. PLoS Med. 2017;14(10):e1002414.","journal-title":"PLoS Med"},{"issue":"3","key":"2866_CR86","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ygyno.2016.06.016","volume":"142","author":"KA Rosenblatt","year":"2016","unstructured":"Rosenblatt KA, Osterbur EF, Douglas JA. Case-control study of cervical cancer and gynecologic screening: a SEER-medicare analysis. Gynecol Oncol. 2016;142(3):395\u2013400.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2866_CR87","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.27844","volume":"132","author":"S Lonnberg","year":"2013","unstructured":"Lonnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit of the Finnish cervical cancer screening program. Int J Cancer. 2013;132(9):2134\u201340.","journal-title":"Int J Cancer"},{"issue":"3","key":"2866_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214486","volume":"14","author":"M Pankakoski","year":"2019","unstructured":"Pankakoski M, Anttila A, Sarkeala T, Heinavaara S. Effectiveness of cervical cancer screening at age 65: a register-based cohort study. PLoS ONE. 2019;14(3):e0214486.","journal-title":"PLoS ONE"},{"issue":"9","key":"2866_CR89","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/aje\/kwu035","volume":"179","author":"AS Rustagi","year":"2014","unstructured":"Rustagi AS, Kamineni A, Weinmann S, Reed SD, Newcomb P, Weiss NS. Cervical screening and cervical cancer death among older women: a population-based, case-control study. Am J Epidemiol. 2014;179(9):1107\u201314.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2866_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/096914139600300107","volume":"3","author":"A Herbert","year":"1996","unstructured":"Herbert A, Breen C, Bryant TN, Hitchcock A, Macdonald H, Millward-Sadler GH, et al. Invasive cervical cancer in Southampton and South West Hampshire: effect of introducing a comprehensive screening programme. J Med Screen. 1996;3(1):23\u20138.","journal-title":"J Med Screen"},{"issue":"9","key":"2866_CR91","first-page":"1653","volume":"24","author":"A Kamineni","year":"2013","unstructured":"Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control. 2013;24(9):1653\u201360.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"2866_CR92","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1620\/tjem.175.171","volume":"175","author":"H Makino","year":"1995","unstructured":"Makino H, Sato S, Yajima A, Komatsu S, Fukao A. Evaluation of the effectiveness of cervical cancer screening: a case-control study in Miyagi, Japan. Tohoku J Exp Med. 1995;175(3):171\u20138.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"2866_CR93","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.32826","volume":"147","author":"R Landy","year":"2020","unstructured":"Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, et al. Impact of screening on cervical cancer incidence: a population-based case-control study in the United States. Int J Cancer. 2020;147(3):887\u201396.","journal-title":"Int J Cancer"},{"issue":"5","key":"2866_CR94","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/bjc.1996.441","volume":"74","author":"BJ Morrison","year":"1996","unstructured":"Morrison BJ, Coldman AJ, Boyes DA, Anderson GH. Forty years of repeated screening: the significance of carcinoma in situ. Br J Cancer. 1996;74(5):814\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"2866_CR95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.24410","volume":"125","author":"P Sasieni","year":"2009","unstructured":"Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer. 2009;125(3):525\u20139.","journal-title":"Int J Cancer"},{"issue":"9","key":"2866_CR96","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/sj.bjc.6601754","volume":"90","author":"M Zappa","year":"2004","unstructured":"Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90(9):1784\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"2866_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1620\/tjem.175.171","volume":"175","author":"H Makino","year":"1995","unstructured":"Makino H, Sato S, Yajima A, Komatsu S, Fukao A. Evaluation of the effectiveness of cervical cancer screening: a case-control study in Miyagi, Japan. Tohoku J Exp Med. 1995;175(3):171\u20138.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"2866_CR98","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/096914139600300307","volume":"3","author":"A Herbert","year":"1996","unstructured":"Herbert A, Stein K, Bryant T, Breen C, Old P. Relation between the incidence of invasive cervical cancer and the screening interval: is a five year interval too long? J Med Screen. 1996;3(3):140\u20135.","journal-title":"J Med Screen"},{"issue":"9","key":"2866_CR99","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/sj.bjc.6601754","volume":"90","author":"M Zappa","year":"2004","unstructured":"Zappa M, Visioli C, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case\u2013control study in Florence. Br J Cancer. 2004;90(9):1784\u20136.","journal-title":"Br J Cancer"},{"issue":"12","key":"2866_CR100","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/ijc.33482","volume":"148","author":"R Aarnio","year":"2021","unstructured":"Aarnio R, Isacson I, Sanner K, Gustavsson I, Gyllensten U, Olovsson M. Comparison of vaginal self-sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: a randomized study. Int J Cancer. 2021;148(12):3051\u20139.","journal-title":"Int J Cancer"},{"issue":"9","key":"2866_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388.","journal-title":"PLoS Med"},{"issue":"4","key":"2866_CR102","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/ijc.32861","volume":"147","author":"KKL Chan","year":"2020","unstructured":"Chan KKL, Liu SS, Wei N, Ngu SF, Chu MMY, Tse KY, et al. Primary HPV testing with cytology versus cytology alone in cervical screening: a prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer. 2020;147(4):1152\u201362.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR103","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ijc.31637","volume":"144","author":"I Gustavsson","year":"2019","unstructured":"Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Sanner K, Wikstrom I, et al. Randomised study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel. Int J Cancer. 2019;144(1):89\u201397.","journal-title":"Int J Cancer"},{"issue":"5","key":"2866_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014788","volume":"7","author":"H Lamin","year":"2017","unstructured":"Lamin H, Eklund C, Elfstr\u00f6m KM, Carlsten-Thor A, Hortlund M, Elfgren K, et al. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56\u201360. BMJ Open. 2017;7(5):e014788.","journal-title":"BMJ Open"},{"key":"2866_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7789","volume":"345","author":"MK Leinonen","year":"2012","unstructured":"Leinonen MK, Nieminen P, L\u00f6nnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.","journal-title":"BMJ"},{"issue":"2","key":"2866_CR106","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.30454","volume":"140","author":"GS Ogilvie","year":"2017","unstructured":"Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440\u20138.","journal-title":"Int J Cancer"},{"issue":"7","key":"2866_CR107","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1684\/bdc.2011.1388","volume":"98","author":"L Piana","year":"2011","unstructured":"Piana L, Leandri FX, Le Retraite L, Heid P, Tamalet C, Sancho-Garnier H. HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhone. [French]. Bull Cancer. 2011;98(7):723\u201331.","journal-title":"Bull Cancer"},{"issue":"9","key":"2866_CR108","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/ijc.32004","volume":"144","author":"NJ Polman","year":"2019","unstructured":"Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer C, Berkhof J. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds. Int J Cancer. 2019;144(9):2339\u201346.","journal-title":"Int J Cancer"},{"issue":"7","key":"2866_CR109","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/jnci\/djn065","volume":"100","author":"G Ronco","year":"2008","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492\u2013501.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2866_CR110","first-page":"2681","volume":"133","author":"H Sancho-Garnier","year":"2013","unstructured":"Sancho-Garnier H, Tamalet C, Halfon P, Leandri F, Retraite LL, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133(11):2681\u20137.","journal-title":"Int J Cancer"},{"issue":"6","key":"2866_CR111","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/bjc.2011.48","volume":"104","author":"A Szarewski","year":"2011","unstructured":"Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening: a randomised controlled trial. Br J Cancer. 2011;104(6):915\u201320.","journal-title":"Br J Cancer"},{"issue":"11","key":"2866_CR112","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/bjc.2017.111","volume":"116","author":"M Viviano","year":"2017","unstructured":"Viviano M, Catarino R, Jeannot E, Boulvain M, Malinverno MU, Vassilakos P, et al. Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br J Cancer. 2017;116(11):1382\u20138.","journal-title":"Br J Cancer"},{"issue":"10","key":"2866_CR113","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41416-022-01954-9","volume":"127","author":"G Aasbo","year":"2022","unstructured":"Aasbo G, Trope A, Nygard M, Christiansen IK, Baasland I, Iversen GA, et al. HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial. Br J Cancer. 2022;127(10):1816\u201326.","journal-title":"Br J Cancer"},{"issue":"8","key":"2866_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003748","volume":"18","author":"KM Elfstrom","year":"2021","unstructured":"Elfstrom KM, Eklund C, Lamin H, Ohman D, Hortlund M, Elfgren K, et al. Organized primary human papillomavirus-based cervical screening: a randomized healthcare policy trial. PLoS Med. 2021;18(8):e1003748.","journal-title":"PLoS Med"},{"issue":"9","key":"2866_CR115","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1055-9965.EPI-22-0340","volume":"31","author":"M Nygard","year":"2022","unstructured":"Nygard M, Engesaeter B, Castle PE, Berland JM, Eide ML, Iversen OE, et al. Randomized implementation of a primary human papillomavirus testing-based cervical cancer screening protocol for women 34 to 69 Years in Norway. Cancer Epidemiol Biomark Prev. 2022;31(9):1812\u201322.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2866_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068776","volume":"377","author":"M Rebolj","year":"2022","unstructured":"Rebolj M, Cuschieri K, Mathews CS, Pesola F, Denton K, Kitchener H. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ. 2022;377:e068776.","journal-title":"BMJ"},{"issue":"9","key":"2866_CR117","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/ijc.27850","volume":"132","author":"N Malila","year":"2013","unstructured":"Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M. The HPV test has similar sensitivity but more overdiagnosis than the Pap test: a randomised health services study on cervical cancer screening in Finland. Int J Cancer. 2013;132(9):2141\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR118","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2018.7464","volume":"320","author":"GS Ogilvie","year":"2018","unstructured":"Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV focal randomized clinical trial. JAMA. 2018;320(1):43\u201352.","journal-title":"JAMA"},{"issue":"9","key":"2866_CR119","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ijc.33900","volume":"150","author":"M Rebolj","year":"2022","unstructured":"Rebolj M, Mathews CS, Pesola F, Castanon A, Kitchener H. Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: observational study. Int J Cancer. 2022;150(9):1412\u201321.","journal-title":"Int J Cancer"},{"issue":"3","key":"2866_CR120","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","volume":"11","author":"G Ronco","year":"2010","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249\u201357.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2866_CR121","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/ijc.32861","volume":"147","author":"KKL Chan","year":"2020","unstructured":"Chan KKL, Liu SS, Wei N, Ngu SF, Chu MMY, Tse KY, et al. Primary HPV testing with cytology versus cytology alone in cervical screening: a prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer. 2020;147(4):1152\u201362.","journal-title":"Int J Cancer"},{"issue":"9","key":"2866_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388.","journal-title":"PLoS Med"},{"issue":"5","key":"2866_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014788","volume":"7","author":"H Lamin","year":"2017","unstructured":"Lamin H, Eklund C, Elfstrom KM, Carlsten-Thor A, Hortlund M, Elfgren K, et al. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56\u201360. BMJ Open. 2017;7(5):e014788.","journal-title":"BMJ Open"},{"issue":"11","key":"2866_CR124","first-page":"2681","volume":"133","author":"H Sancho-Garnier","year":"2013","unstructured":"Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133(11):2681\u20137.","journal-title":"Int J Cancer"},{"issue":"3","key":"2866_CR125","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","volume":"11","author":"G Ronco","year":"2010","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249\u201357.","journal-title":"Lancet Oncol"},{"key":"2866_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7789","volume":"345","author":"MK Leinonen","year":"2012","unstructured":"Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.","journal-title":"BMJ"},{"issue":"S1","key":"2866_CR127","first-page":"A77","volume":"95","author":"G Ogilvie","year":"2019","unstructured":"Ogilvie G, Van Niekerk D, Krajden M, Smith L, Cook D, Martin R, et al. HPV focal 48 month exit results by age for women HPV or LBC negative at baseline screening. Sex Transm Infect. 2019;95(S1):A77.","journal-title":"Sex Transm Infect"},{"issue":"2","key":"2866_CR128","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.30454","volume":"140","author":"GS Ogilvie","year":"2017","unstructured":"Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440\u20138.","journal-title":"Int J Cancer"},{"issue":"7","key":"2866_CR129","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/ijc.32524","volume":"146","author":"AJ Coldman","year":"2020","unstructured":"Coldman AJ, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. Int J Cancer. 2020;146(7):1810\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"2866_CR130","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","volume":"20","author":"NJ Polman","year":"2019","unstructured":"Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229\u201338.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2866_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119755","volume":"10","author":"T Agorastos","year":"2015","unstructured":"Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, et al. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS ONE. 2015;10(3):e0119755.","journal-title":"PLoS ONE"},{"issue":"3","key":"2866_CR132","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/LGT.0b013e3181cd6d36","volume":"14","author":"A Balasubramanian","year":"2010","unstructured":"Balasubramanian A, Kulasingam SL, Baer A, Hughes JP, Myers ER, Mao C, et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk HPV DNA testing of self-collected vaginal samples. J Low Genit Trcat Dis. 2010;14(3):185\u201395.","journal-title":"J Low Genit Trcat Dis"},{"issue":"5","key":"2866_CR133","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/cncy.21544","volume":"123","author":"AJ Blatt","year":"2015","unstructured":"Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282\u20138.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"2866_CR134","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ygyno.2016.04.027","volume":"142","author":"K Chatzistamatiou","year":"2016","unstructured":"Chatzistamatiou K, Moysiadis T, Moschaki V, Panteleris N, Agorastos T. Comparison of cytology, HPV DNA testing and HPV 16\/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecol Oncol. 2016;142(1):120\u20137.","journal-title":"Gynecol Oncol"},{"key":"2866_CR135","doi-asserted-by":"crossref","unstructured":"Cox JT, Castle PE, Behrens CM, Sharma A, Wright Jr TC, Cuzick J, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184. e1-. e11.","DOI":"10.1016\/j.ajog.2012.11.020"},{"issue":"4","key":"2866_CR136","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1055-9965.EPI-10-0818","volume":"20","author":"CE Depuydt","year":"2011","unstructured":"Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers Prev. 2011;20(4):628\u201337.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9194","key":"2866_CR137","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/S0140-6736(99)04110-0","volume":"354","author":"P Hillemanns","year":"1999","unstructured":"Hillemanns P, Kimmig R, H\u00fcttemann U, Dannecker C, Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet. 1999;354(9194):1970.","journal-title":"Lancet"},{"issue":"16","key":"2866_CR138","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa071430","volume":"357","author":"M-H Mayrand","year":"2007","unstructured":"Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579\u201388.","journal-title":"N Engl J Med"},{"issue":"3","key":"2866_CR139","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ijc.25726","volume":"129","author":"J Monsonego","year":"2011","unstructured":"Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrj\u00e4nen K, Halfon P, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691\u2013701.","journal-title":"Int J Cancer"},{"key":"2866_CR140","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejogrb.2019.01.008","volume":"234","author":"T Song","year":"2019","unstructured":"Song T, Seong SJ, Lee SK, Kim BR, Ju W, Kim KH, et al. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia. Eur J Obstet Gynecol Reprod Biol. 2019;234:112\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"2866_CR141","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1258\/096914107780154486","volume":"14","author":"A Szarewski","year":"2007","unstructured":"Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen. 2007;14(1):34\u201342.","journal-title":"J Med Screen"},{"issue":"2","key":"2866_CR142","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","volume":"24","author":"RB Perkins","year":"2020","unstructured":"Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102\u201331.","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"2866_CR143","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/curroncol30060431","volume":"30","author":"K Willows","year":"2023","unstructured":"Willows K, Selk A, Auclair M-H, Jim B, Jumah N, Nation J, et al. 2023 Canadian colposcopy guideline: a risk-based approach to management and surveillance of cervical dysplasia. Curr Oncol. 2023;30(6):5738\u201368.","journal-title":"Curr Oncol"},{"issue":"10","key":"2866_CR144","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/pon.2003","volume":"21","author":"M Drolet","year":"2012","unstructured":"Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology. 2012;21(10):1071\u201381.","journal-title":"Psychooncology"},{"issue":"2","key":"2866_CR145","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejogrb.2013.03.033","volume":"169","author":"A Heinonen","year":"2013","unstructured":"Heinonen A, Tapper AM, Leminen A, Sintonen H, Roine RP. Health-related quality of life and perception of anxiety in women with abnormal cervical cytology referred for colposcopy: an observational study. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):387\u201391.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"2866_CR146","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/hec.1278","volume":"17","author":"K Howard","year":"2008","unstructured":"Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593\u2013605.","journal-title":"Health Econ"},{"issue":"4","key":"2866_CR147","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jval.2010.11.017","volume":"14","author":"EL Jewell","year":"2011","unstructured":"Jewell EL, Smrtka M, Broadwater G, Valea F, Davis DM, Nolte KC, et al. Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health. 2011;14(4):582\u20136.","journal-title":"Value Health"},{"issue":"5","key":"2866_CR148","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29119","volume":"121","author":"EE Kent","year":"2015","unstructured":"Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121(5):758\u201365.","journal-title":"Cancer"},{"issue":"5","key":"2866_CR149","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.ijrobp.2008.06.1905","volume":"73","author":"IJ Korfage","year":"2009","unstructured":"Korfage IJ, Essink-Bot ML, Mols F, van de Poll-Franse L, Kruitwagen R, van Ballegooijen M. Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys. 2009;73(5):1501\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2866_CR150","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ygyno.2013.11.001","volume":"132","author":"IJ Korfage","year":"2014","unstructured":"Korfage IJ, Essink-Bot ML, Westenberg SM, Helmerhorst T, Habbema JD, van Ballegooijen M. How distressing is referral to colposcopy in cervical cancer screening? A prospective quality of life study. Gynecol Oncol. 2014;132(1):142\u20138.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2866_CR151","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2009.07.003","volume":"46","author":"IJ Korfage","year":"2010","unstructured":"Korfage IJ, van Ballegooijen M, Huveneers H, Essink-Bot ML. Anxiety and borderline PAP smear results. Eur J Cancer. 2010;46(1):134\u201341.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2866_CR152","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ygyno.2010.05.002","volume":"118","author":"M Kuppermann","year":"2010","unstructured":"Kuppermann M, Melnikow J, Slee C, Tancredi DJ, Kulasingam S, Birch S, et al. Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol. 2010;118(2):108\u201315.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2866_CR153","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/sj.bjc.6602411","volume":"92","author":"E Maissi","year":"2005","unstructured":"Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer. 2005;92(6):990\u20134.","journal-title":"Br J Cancer"},{"issue":"1","key":"2866_CR154","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clinthera.2014.11.002","volume":"37","author":"A Marcellusi","year":"2015","unstructured":"Marcellusi A, Capone A, Favato G, Mennini FS, Baio G, Haeussler K, et al. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Clin Ther. 2015;37(1):156-67.e4.","journal-title":"Clin Ther"},{"issue":"8","key":"2866_CR155","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.clinthera.2011.06.012","volume":"33","author":"FS Mennini","year":"2011","unstructured":"Mennini FS, Panatto D, Marcellusi A, Cristoforoni P, De Vincenzo R, Di Capua E, et al. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy. Clin Ther. 2011;33(8):1084-95.e4.","journal-title":"Clin Ther"},{"issue":"22","key":"2866_CR156","doi-asserted-by":"publisher","first-page":"9679","DOI":"10.7314\/APJCP.2014.15.22.9679","volume":"15","author":"H Murasawa","year":"2014","unstructured":"Murasawa H, Konno R, Okubo I, Arakawa I. Evaluation of health-related quality of life for hypothesized medical states associated with cervical cancer. Asian Pac J Cancer Prev. 2014;15(22):9679\u201385.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2866_CR157","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12955-016-0566-8","volume":"14","author":"M Ock","year":"2016","unstructured":"Ock M, Park JY, Son WS, Lee HJ, Kim SH, Jo MW. Estimation of utility weights for human papilloma virus-related health states according to disease severity. Health Qual Life Outcomes. 2016;14(1):163.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"2866_CR158","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/sti.2009.037028","volume":"85","author":"M Pirotta","year":"2009","unstructured":"Pirotta M, Ung L, Stein A, Conway EL, Mast TC, Fairley CK, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect. 2009;85(7):508\u201313.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"2866_CR159","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/jwh.2019.7858","volume":"29","author":"R Shah","year":"2020","unstructured":"Shah R, Nwankwo C, Kwon Y, Corman SL. Economic and humanistic burden of cervical cancer in the United States: results from a nationally representative survey. J Womens Health. 2020;29(6):799\u2013805.","journal-title":"J Womens Health"},{"key":"2866_CR160","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1186\/1756-0500-7-899","volume":"7","author":"L Simonella","year":"2014","unstructured":"Simonella L, Howard K, Canfell K. A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes. 2014;7:899.","journal-title":"BMC Res Notes"},{"key":"2866_CR161","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1477-7525-6-94","volume":"6","author":"Whynes DK, Group T","year":"2008","unstructured":"Whynes DK, Group T. Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes. 2008;6:94.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2866_CR162","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14737167.2021.1906224","volume":"22","author":"K Katanyoo","year":"2022","unstructured":"Katanyoo K, Thavorncharoensap M, Chaikledkaew U, Riewpaiboon A. A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):107\u201317.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"2866_CR163","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.pec.2016.04.002","volume":"99","author":"K Phillips","year":"2016","unstructured":"Phillips K, Hersch J, Turner R, Jansen J, McCaffery K. The influence of the \u2018cancer effect\u2019 on young women\u2019s responses to overdiagnosis in cervical screening. Patient Educ Couns. 2016;99(10):1568\u201375.","journal-title":"Patient Educ Couns"},{"key":"2866_CR164","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2147\/PPA.S193522","volume":"13","author":"AE van der Meij","year":"2019","unstructured":"van der Meij AE, Damman OC, Uiters E, Timmermans DR. What benefits and harms are important for a decision about cervical screening? A study of the perspective of different subgroups of women. Patient Prefer Adherence. 2019;13:1005\u201317.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"2866_CR165","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/hec.1054","volume":"15","author":"Z Philips","year":"2006","unstructured":"Philips Z, Whynes DK, Avis M. Testing the construct validity of willingness to pay valuations using objective information about risk and health benefit. Health Econ. 2006;15(2):195\u2013204.","journal-title":"Health Econ"},{"issue":"8","key":"2866_CR166","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/jech.57.8.589","volume":"57","author":"P Adab","year":"2003","unstructured":"Adab P, Marshall T, Rouse A, Randhawa B, Sangha H, Bhangoo N. Randomised controlled trial of the effect of evidence based information on women\u2019s willingness to participate in cervical cancer screening. J Epidemiol Community Health. 2003;57(8):589\u201393.","journal-title":"J Epidemiol Community Health"},{"key":"2866_CR167","unstructured":"Alberta PROMs & EQ-5D Research & Support Unit. Alberta Population Norms for EQ-5D-5L, 2018. Available from: https:\/\/sites.google.com\/ualberta.ca\/apersu\/about-eq-5d\/eq-5d-population-norms. Accessed 7 July 2024."},{"issue":"1","key":"2866_CR168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170371","volume":"12","author":"A Acera","year":"2017","unstructured":"Acera A, Manresa JM, Rodriguez D, Rodriguez A, Bonet JM, Trapero-Bertran M, et al. Increasing cervical cancer screening coverage: a randomised, community-based clinical trial. PLoS ONE. 2017;12(1):e0170371.","journal-title":"PLoS ONE"},{"issue":"7","key":"2866_CR169","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ijc.22484","volume":"120","author":"AG Bais","year":"2007","unstructured":"Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer. 2007;120(7):1505\u201310.","journal-title":"Int J Cancer"},{"issue":"9","key":"2866_CR170","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ijc.28545","volume":"134","author":"G Broberg","year":"2014","unstructured":"Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134(9):2223\u201330.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR171","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ijc.27985","volume":"133","author":"G Broberg","year":"2013","unstructured":"Broberg G, Jonasson JM, Ellis J, Gyrd-Hansen D, Anjemark B, Glantz A, et al. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. Int J Cancer. 2013;133(1):164\u201371.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR172","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0969141314558785","volume":"22","author":"L Cadman","year":"2015","unstructured":"Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening. J Med Screen. 2015;22(1):28\u201337.","journal-title":"J Med Screen"},{"issue":"3","key":"2866_CR173","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1055-9965.346.13.3","volume":"13","author":"S Eaker","year":"2004","unstructured":"Eaker S, Adami HO, Granath F, Wilander E, Sparen P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(3):346\u201354.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"2866_CR174","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/ijc.32374","volume":"145","author":"KM Elfstrom","year":"2019","unstructured":"Elfstrom KM, Sundstrom K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, et al. Increasing participation in cervical screening by targeting long-term nonattenders: randomized health services study. Int J Cancer. 2019;145(11):3033\u20139.","journal-title":"Int J Cancer"},{"issue":"4","key":"2866_CR175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151978","volume":"11","author":"E Enerly","year":"2016","unstructured":"Enerly E, Bonde J, Schee K, Pedersen H, Lonnberg S, Nygard M. Self-sampling for human papillomavirus testing among non-attenders increases attendance to the Norwegian cervical cancer screening programme. PLoS ONE. 2016;11(4):e0151978.","journal-title":"PLoS ONE"},{"issue":"4","key":"2866_CR176","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/bjc.2015.11","volume":"112","author":"P Giorgi Rossi","year":"2015","unstructured":"Giorgi Rossi P, Fortunato C, Barbarino P, Boveri S, Caroli S, Del Mistro A, et al. Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter. Br J Cancer. 2015;112(4):667\u201375.","journal-title":"Br J Cancer"},{"issue":"2","key":"2866_CR177","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/sj.bjc.6606040","volume":"104","author":"P Giorgi Rossi","year":"2011","unstructured":"Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer. 2011;104(2):248\u201354.","journal-title":"Br J Cancer"},{"key":"2866_CR178","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1040","volume":"340","author":"M Gok","year":"2010","unstructured":"Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040.","journal-title":"BMJ"},{"issue":"5","key":"2866_CR179","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ijc.26128","volume":"130","author":"M Gok","year":"2012","unstructured":"Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer. 2012;130(5):1128\u201335.","journal-title":"Int J Cancer"},{"issue":"11","key":"2866_CR180","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/bjc.2014.510","volume":"111","author":"K Haguenoer","year":"2014","unstructured":"Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, et al. Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer. 2014;111(11):2187\u201396.","journal-title":"Br J Cancer"},{"issue":"4","key":"2866_CR181","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000327527","volume":"55","author":"D Heranney","year":"2011","unstructured":"Heranney D, Fender M, Velten M, Baldauf JJ. A prospective randomized study of two reminding strategies: telephone versus mail in the screening of cervical cancer in women who did not initially respond. Acta Cytol. 2011;55(4):334\u201340.","journal-title":"Acta Cytol"},{"issue":"4","key":"2866_CR182","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2478\/raon-2018-0036","volume":"52","author":"U Ivanus","year":"2018","unstructured":"Ivanus U, Jerman T, Fokter AR, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol. 2018;52(4):399\u2013412.","journal-title":"Radiol Oncol"},{"issue":"4","key":"2866_CR183","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ijc.31391","volume":"143","author":"E Kellen","year":"2018","unstructured":"Kellen E, Benoy I, Vanden Broeck D, Martens P, Bogers JP, Haelens A, et al. A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program. Int J Cancer. 2018;143(4):861\u20138.","journal-title":"Int J Cancer"},{"issue":"7","key":"2866_CR184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235202","volume":"15","author":"C Lilliecreutz","year":"2020","unstructured":"Lilliecreutz C, Karlsson H, Spetz Holm AC. Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women\u2019s own preferred test method into account: a Swedish randomised controlled trial. PLoS ONE. 2020;15(7):e0235202.","journal-title":"PLoS ONE"},{"issue":"11","key":"2866_CR185","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013728","volume":"6","author":"S Lonnberg","year":"2016","unstructured":"Lonnberg S, Andreassen T, Engesaeter B, Lilleng R, Kleven C, Skare A, et al. Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention. BMJ Open. 2016;6(11):e013728.","journal-title":"BMJ Open"},{"issue":"6","key":"2866_CR186","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/CEJ.0b013e3280145e60","volume":"16","author":"MG Oscarsson","year":"2007","unstructured":"Oscarsson MG, Benzein EG, Wijma BE, Carlsson PG. Promotion of cervical screening among nonattendees: a partial cost-effectiveness analysis. Eur J Cancer Prev. 2007;16(6):559\u201363.","journal-title":"Eur J Cancer Prev"},{"issue":"9","key":"2866_CR187","volume":"55","author":"J Paulauskiene","year":"2019","unstructured":"Paulauskiene J, Ivanauskiene R, Skrodeniene E, Petkeviciene J. Organised versus opportunistic cervical cancer screening in urban and rural regions of Lithuania. Medicina (B Aires). 2019;55(9):06.","journal-title":"Medicina (B Aires)"},{"key":"2866_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2020.100194","volume":"9","author":"E Peeters","year":"2020","unstructured":"Peeters E, Cornet K, Cammu H, Verhoeven V, Devroey D, Arbyn M. Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken: a randomised controlled trial. Papillomavirus Res. 2020;9:100194.","journal-title":"Papillomavirus Res"},{"issue":"4","key":"2866_CR189","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1258\/096914105775220741","volume":"12","author":"K Stein","year":"2005","unstructured":"Stein K, Lewendon G, Jenkins R, Davis C. Improving uptake of cervical cancer screening in women with prolonged history of non-attendance for screening: a randomized trial of enhanced invitation methods. J Med Screen. 2005;12(4):185\u20139.","journal-title":"J Med Screen"},{"issue":"1","key":"2866_CR190","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4165-4","volume":"18","author":"M Tranberg","year":"2018","unstructured":"Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures. A randomized controlled trial. BMC Cancer. 2018;18(1):273.","journal-title":"BMC Cancer"},{"issue":"3","key":"2866_CR191","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bjc.2011.236","volume":"105","author":"I Wikstrom","year":"2011","unstructured":"Wikstrom I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer. 2011;105(3):337\u20139.","journal-title":"Br J Cancer"},{"issue":"2","key":"2866_CR192","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0738-3991(02)00119-2","volume":"50","author":"ML Jibaja-Weiss","year":"2003","unstructured":"Jibaja-Weiss ML, Volk RJ, Kingery P, Smith QW, Holcomb JD. Tailored messages for breast and cervical cancer screening of low-income and minority women using medical records data. Patient Educ Couns. 2003;50(2):123\u201332.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"2866_CR193","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/LGT.0000000000000195","volume":"20","author":"J Murphy","year":"2016","unstructured":"Murphy J, Mark H, Anderson J, Farley J, Allen J. A randomized trial of human papillomavirus self-sampling as an intervention to promote cervical cancer screening among women with HIV. J Low Genit Tract Dis. 2016;20(2):139\u201344.","journal-title":"J Low Genit Tract Dis"},{"issue":"9","key":"2866_CR194","first-page":"1081","volume":"27","author":"SM Peitzmeier","year":"2016","unstructured":"Peitzmeier SM, Khullar K, Potter J. Effectiveness of four outreach modalities to patients overdue for cervical cancer screening in the primary care setting: a randomized trial. Cancer Causes Control. 2016;27(9):1081\u201391.","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2866_CR195","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0091-7435(03)00165-8","volume":"37","author":"B Valanis","year":"2003","unstructured":"Valanis B, Whitlock EE, Mullooly J, Vogt T, Smith S, Chen C, et al. Screening rarely screened women: time-to-service and 24-month outcomes of tailored interventions. Prev Med. 2003;37(5):442\u201350.","journal-title":"Prev Med"},{"issue":"1","key":"2866_CR196","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1006\/pmed.2001.0949","volume":"34","author":"BG Valanis","year":"2002","unstructured":"Valanis BG, Glasgow RE, Mullooly J, Vogt TM, Whitlock EP, Boles SM, et al. Screening HMO women overdue for both mammograms and pap tests. Prev Med. 2002;34(1):40\u201350.","journal-title":"Prev Med"},{"issue":"8","key":"2866_CR197","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1089\/154099903322447756","volume":"12","author":"TM Vogt","year":"2003","unstructured":"Vogt TM, Glass A, Glasgow RE, La Chance PA, Lichtenstein E. The safety net: a cost-effective approach to improving breast and cervical cancer screening. J Womens Health. 2003;12(8):789\u201398.","journal-title":"J Womens Health"},{"issue":"11","key":"2866_CR198","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14729","volume":"2","author":"RL Winer","year":"2019","unstructured":"Winer RL, Lin J, Tiro JA, Miglioretti DL, Beatty T, Gao H, et al. Effect of mailed human papillomavirus test kits vs usual care reminders on cervical cancer screening uptake, precancer detection, and treatment: a randomized clinical trial. JAMA Netw Open. 2019;2(11):e1914729.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2866_CR199","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1089\/jwh.2012.4203","volume":"22","author":"KM Decker","year":"2013","unstructured":"Decker KM, Turner D, Demers AA, Martens PJ, Lambert P, Chateau D. Evaluating the effectiveness of cervical cancer screening invitation letters. J Womens Health. 2013;22(8):687\u201393.","journal-title":"J Womens Health"},{"issue":"3","key":"2866_CR200","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3747\/co.26.4575","volume":"26","author":"F Jalili","year":"2019","unstructured":"Jalili F, O\u2019Conaill C, Templeton K, Lotocki R, Fischer G, Manning L, et al. Assessing the impact of mailing self-sampling kits for human papillomavirus testing to unscreened non-responder women in Manitoba. Curr Oncol. 2019;26(3):167\u201372.","journal-title":"Curr Oncol"},{"issue":"6","key":"2866_CR201","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3122\/jabfm.2018.06.170369","volume":"31","author":"T Kiran","year":"2018","unstructured":"Kiran T, Davie S, Moineddin R, Lofters A. Mailed letter versus phone call to increase uptake of cancer screening: a pragmatic, randomized trial. J Am Board Fam Med. 2018;31(6):857\u201368.","journal-title":"J Am Board Fam Med"},{"issue":"5","key":"2866_CR202","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/jwh.2015.5348","volume":"25","author":"CS Racey","year":"2016","unstructured":"Racey CS, Gesink DC, Burchell AN, Trivers S, Wong T, Rebbapragada A. Randomized intervention of self-collected sampling for human papillomavirus testing in under-screened rural women: uptake of screening and acceptability. J Womens Health. 2016;25(5):489\u201397.","journal-title":"J Womens Health"},{"issue":"1","key":"2866_CR203","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1467-842X.2005.tb00753.x","volume":"29","author":"S Morrell","year":"2005","unstructured":"Morrell S, Taylor R, Zeckendorf S, Niciak A, Wain G, Ross J. How much does a reminder letter increase cervical screening among under-screened women in NSW? Aust N Z J Public Health. 2005;29(1):78\u201384.","journal-title":"Aust N Z J Public Health"},{"issue":"3\u20134","key":"2866_CR204","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.canep.2009.08.007","volume":"33","author":"RM Mullins","year":"2009","unstructured":"Mullins RM. Can older women be motivated to attend for their final Papanicolaou tests? The use of targeted and general personalised reminder letters. Cancer Epidemiol. 2009;33(3\u20134):306\u20138.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"2866_CR205","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.30031","volume":"139","author":"F Sultana","year":"2016","unstructured":"Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, et al. Home-based HPV self-sampling improves participation by never-screened and under-screened women: results from a large randomized trial (iPap) in Australia. Int J Cancer. 2016;139(2):281\u201390.","journal-title":"Int J Cancer"},{"issue":"1","key":"2866_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-014-0055-7","volume":"73","author":"H Fujiwara","year":"2015","unstructured":"Fujiwara H, Shimoda A, Ishikawa Y, Taneichi A, Ohashi M, Takahashi Y, et al. Effect of providing risk information on undergoing cervical cancer screening: a randomized controlled trial. Arch Public Health. 2015;73(1):7.","journal-title":"Arch Public Health"},{"issue":"2","key":"2866_CR207","first-page":"55","volume":"62","author":"M Yamasaki","year":"2019","unstructured":"Yamasaki M, Abe S, Miura K, Masuzaki H. The effect of self-sampled HPV testing on participation in cervical cancer screening on a remote island. Acta Med Nagasaki. 2019;62(2):55\u201361.","journal-title":"Acta Med Nagasaki"},{"issue":"Suppl","key":"2866_CR208","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.ypmed.2013.02.001","volume":"57","author":"F Abdullah","year":"2013","unstructured":"Abdullah F, Su TT. Applying the transtheoretical model to evaluate the effect of a call-recall program in enhancing Pap smear practice: a cluster randomized trial. Prev Med. 2013;57(Suppl):S83\u20136.","journal-title":"Prev Med"},{"key":"2866_CR209","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2866_CR210","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/bmjsrh-2022-201515","volume":"48","author":"J Nothacker","year":"2022","unstructured":"Nothacker J, Nury E, Roebl Mathieu M, Raatz H, Meerpohl JJ, Schmucker C. Women\u2019s attitudes towards a human papillomavirus-based cervical cancer screening strategy: a systematic review. BMJ Sex Reprod Health. 2022;48(4):295\u2013306.","journal-title":"BMJ Sex Reprod Health"},{"issue":"9916","key":"2866_CR211","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524\u201332.","journal-title":"Lancet"},{"key":"2866_CR212","unstructured":"International Agency for Research on Cancer. Volume 18: Cervical cancer screening. 2022. In: IARC Handbooks of Cancer Prevention. Available from: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Handbooks-Of-Cancer-Prevention\/Cervical-Cancer-Screening-2022 . Accessed 7 July 2024."},{"issue":"2","key":"2866_CR213","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ijc.33967","volume":"151","author":"M Arbyn","year":"2022","unstructured":"Arbyn M, Castle PE, Schiffman M, Wentzensen N, Heckman-Stoddard B, Sahasrabuddhe VV. Meta-analysis of agreement\/concordance statistics in studies comparing self- vs clinician-collected samples for HPV testing in cervical cancer screening. Int J Cancer. 2022;151(2):308\u201312.","journal-title":"Int J Cancer"},{"issue":"3","key":"2866_CR214","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijgo.2015.07.024","volume":"132","author":"RA Mustafa","year":"2016","unstructured":"Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, et al. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016;132(3):259\u201365.","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"2866_CR215","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220148","volume":"14","author":"L Li","year":"2019","unstructured":"Li L, Severens JLH, Mandrik O. Disutility associated with cancer screening programs: a systematic review. PLoS ONE. 2019;14(7):e0220148.","journal-title":"PLoS ONE"},{"key":"2866_CR216","doi-asserted-by":"crossref","unstructured":"\u00d3 Ceilleachair A, O\u2019Mahony JF, O\u2019Connor M, O\u2019Leary J, Normand C, Martin C, et a;. Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: a systematic review. Qual Life Res. 2017;26(11):2885\u201397.","DOI":"10.1007\/s11136-017-1628-z"},{"issue":"3","key":"2866_CR217","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001351","volume":"4","author":"PT Yeh","year":"2019","unstructured":"Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Health. 2019;4(3):e001351.","journal-title":"BMJ Glob Health"},{"key":"2866_CR218","doi-asserted-by":"crossref","unstructured":"Catarino RR, Vassilakos PP, Royannez D, II, Guillot CC, Alzuphar SS, Fehlmann AA, et al. Barriers to cervical cancer screening in Geneva (DEPIST Study). J. 2016;20(2):135\u20138.","DOI":"10.1097\/LGT.0000000000000173"}],"updated-by":[{"DOI":"10.1186\/s13643-025-03061-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000}}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02866-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02866-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02866-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:16:09Z","timestamp":1768342569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-025-02866-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":218,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2866"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02866-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4677378\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the competing interests section was corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13643-025-03061-1","URL":"https:\/\/doi.org\/10.1186\/s13643-025-03061-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG is currently an employee of the Canada's Drug Agency (CDA). The current work was unrelated to her employment and CDA had no role in the funding, design, or oversight of the work. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}